All In Biotech

Drug Trial Radar · NCT03925233

Breast Cancer Treatment Based on Organ-like Culture

Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 2, 2019

Primary completion

Dec 15, 2021

Study completion Dec 15, 2021

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 24, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Conditions

  • Breast Cancer Organoids

Interventions

  • TrastuzumabDrug

    Trastuzumab Injection

  • Doxorubicin HydrochlorideDrug

    Doxorubicin Hydrochloride Injection

  • Epirubicin hydrochlorideDrug

    Epirubicin hydrochloride injection

  • FluorouracilDrug

    Fluorouracil injection

  • PaclitaxelDrug

    Paclitaxel injection

  • GemcitabineDrug

    Gemcitabine injection

  • CisplatinDrug

    Cisplatin injection

  • Recombinant Human EndostatinDrug

    Recombinant Human Endostatin Injection

  • Pirarubicin hydrochlorideDrug

    Pirarubicin hydrochloride injection

  • PyrrolidineDrug

    Pyrrolidine tablets

  • IxabepiloneDrug

    Ixapilone Injection

  • Tamoxifen citrateDrug

    Tamoxifen citrate tablets

  • Vinorelbine tartrateDrug

    Vinorelbine tartrate injection

  • CarboplatinDrug

    Carboplatin injection

  • MethotrexateDrug

    Methotrexate injection

  • Eribulin mesylateDrug

    Eribulin mesylate injection

  • Toremifene citrateDrug

    Toremifene citrate tablets

  • AnastrozoleDrug

    Anastrozole tablets

  • LetrozoleDrug

    Letrozole tablets

  • ExemestaneDrug

    Exemestane tablets

  • FulvestrantDrug

    Fulvestrant injection

  • OlaparibDrug

    Olapani pill

  • BevacizumabDrug

    Bevacizumab injection

  • Apatinib mesylateDrug

    Apatinib mesylate tablets

  • PattozumabDrug

    Pattozumab injection

  • CapecitabineDrug

    Capecitabine tablets

  • Ear particlesDrug

    Ear particles

  • Aidi InjectionDrug

    Aidi Injection

  • CyclophosphamideDrug

    Cyclophosphamide injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection of cell viabilityTime frame: 8 weeks before neoadjuvant chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JingSu

    Xi'an, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.